tested negative to HLA-B*57:01. [10, 11] On account of this, HIV treatment guidelines now recommend screening for HLA-B*57:01 prior to initiating ABC, and persons who test positive should not receive ABC. [12] The prevalence of HLA-B*57:01 allele has been shown to vary widely amongst populations tested, with low prevalence rates reported amongst people of African descent. [13] [14] [15] In North America, the prevalence has been reported to be higher amongst Caucasians (7.2%) than African-Americans (2.8%). [16] Few prevalence studies have been carried out in sub-Saharan African where about 80% of persons living with HIV (PLHIV) reside and none has been done in Nigeria, the country with the second-highest number of PLHIV. The objective of this study was to determine the prevalence of the genetic marker HLA-B*57:01 amongst Nigerians living with HIV/acquired immune deficiency syndrome. 
Methods

Ethics statement
Study design
We conducted a multicentre cross-sectional survey amongst adults with HIV-infection across five HIV treatment facilities in Nigeria. The study sites were chosen based on geographic distribution to capture the ethnic diversity of the country. The study locations were Jos (North-Central), Lagos (South-West), Makurdi (Middle belt), Yenagoa (South-South) and Zaria (North).
Sample size
The minimum sample size for the study was obtained using an online sample size calculator (select-statistics.co.uk/ calculators/sample-size-calculator-population-proportion), accessed on the 3 rd of September 2013. A minimum sample size of 753 was required based on an estimated prevalence of HLA B27 01 allele of 2%, an error margin of 1% and a 95% confidence interval. [16] Our target enrolment was to 1500 participants, with 300 participants recruited at each of the study sites.
Patient recruitment and data and sample collection
Eligible participants were adults >18 years, with confirmed HIV-infection. Between April 2016 and 2017, consecutive adults presenting to the study sites were approached to participate in the study during their routine clinic visits. Each study participant gave written informed consent prior to the study enrolment. Demographic information and history of ABC exposure were obtained from each participant, and 3 ml of venous blood was obtained from each participant in bottles with ethylenediaminetetraacetic acid for HLA typing. Blood samples at each study site were batched and transported once a week to a central laboratory for the analysis.
DNA extraction
The DNA from the blood samples was extracted using the Gentra Puregene Plus (1000 ml) Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. [17] This kit was best suited for the study because of its high-volume sample processing and high DNA elution yield. The ratio of sample volume, lysis solutions, protein precipitation solution and wash buffers used were in accordance to the manufacturer's protocol. In addition, to completely eliminate all traces of RNA, RNase A solution was added during extraction, therefore yielding only pure DNA. The final elution volume of 300 µl was quantified with a spectrophotometer at A260/280 nm ratio (SmartSpec Plus, Bio-Rad, Spain). All samples were stored at −40°C prior to further analyses.
Human leukocyte antigen typing
Samples were initially assessed using non-specific low-resolution HLA-B*5701 primer mix containing various subtypes of the B57 gene (OLERUP GmbH, Vienna, Austria). The samples found to be HLA-B*57 positive were further subjected to a high-resolution screening using sequence-specific primer methodology. Low-resolution reaction included 30-60 ng/µl of DNA, bulk primer solution and polymerase chain reaction (PCR) Master Mix (OLERUP GmbH, Vienna, Austria) in accordance to the manufacturer's protocol. DNA samples with concentrations below 15 ng/µl were exempted from PCR amplification due to failed amplification revealed during our pilot analysis for this study.
For high-resolution analysis, PCR-sequence-specific-primer methodology was used. 50 ng/µl of DNA, PCR Master Mix complete with Taq (OLERUP GmbH, Vienna, Austria) and water were added to each well pre-aliquoted primer solutions in 0.2-ml well cut PCR plate. Thermocycling parameters for both low-resolution amplification and high-resolution amplification included initial denaturation at 94°C for 2 min followed by 10 cycles of 94°C for 10 s and 10 cycles of annealing and extension at 65°C for 60 s. Afterwards, the second phase of denaturation was carried out at 94° C for 10 sec, followed by 20 cycles of annealing at 61° C for 50 sec and extension at 72°C for 30 sec. Ramp rate of thermal cycler was reduced to 1°C/s at every step. PCR products were electrophoresed on a 2% agarose gel (Bio-Rad, Spain).
Data analysis
Demographic information was summarised using descriptive statistics. The prevalence of HLA-B*57:01:01 allele was reported as a percentage. Statistical analysis was carried out using STATA version 14, College Station, Texas, USA.
results
A total of 1504 patients were enrolled in the study. The mean age was 44.6 ± 10.7 years, and 1078 (71.7%) were female. A total of 1463 (97.3%) patients were on ART. ABC use was documented in 12 (0.8%) patients. None of the patients reported a diagnosis of HSR to ABC. Table 1 summarises demographic characteristics of the study population.
One thousand and five hundred (1500) blood samples were suitable for the analysis (4 sample spilled) and 1458 (97.2%) were successfully typed. A total of 132 (9.1%) were HLA-B57* positive using non-specific low-resolution HLA-B*57:01 primer mix. On further analysis, none of the 132 samples (0%) had the HLA-B*57:01 allele. Table 2 shows the frequency of HLA-B57* identified in our patient population.
dIscussIon
Our aim was to determine the prevalence of HLA-B*57:01 allele in the Nigerian population. To the best of our knowledge, this is the first published report of HLA-B*57:01 allele in Nigeria. None of the patients in our study population had the HLA-B*57:01, although other closely related alleles were identified. These closely related alleles are not associated with HSR to ABC. However, HLA-B*57:03 which was one of the most frequent alleles found is associated with slow progression of HIV. [18] The clinical significance of the other identified alleles is yet to be determined.
Our results support emerging data indicating a low prevalence of HLA-B*57:01 allele amongst Africans. The PREDICT-1 study which enrolled 1956 participants across 19 countries reported a prevalence of 2.8% in Africans/African Americans and 7.2% amongst Caucasians in North America. [16] In another large epidemiologic study in the UK which enrolled 1494 subjects, 770 (52%) were black, and the prevalence was 0.26% in blacks compared to 7.93% in whites. Few prevalence studies have been carried out in Africa; in Kenya, a prevalence of 0.8% was recently reported amongst 1004 samples analysed, [19] whereas none (0%) of the 161 samples from HIV-infected patients in Uganda had the HLA-B*57:01 allele. [20] Very few participants in our study cohort (0.8%) had prior exposure to ABC and none reported symptoms suggestive of HSR. The low frequency of exposure to ABC in this population may be related to the uncertain risk of ABC hypersensitivity. Given the strong association between HLA-B*57:01 and ABC HSR, our study suggests that the risk for ABC HSR in our population is low. While the current guidelines recommend routine screening for HLA-B*57:01 prior to ABC initiation, the cost-effectiveness of this recommendation needs to be evaluated in Nigeria and other countries with very low prevalence of HLA-B*5701.
Our study had some limitations. While our study sites were chosen to capture the ethnic diversity of Nigeria, we cannot confirm that our participants included members of the over 250 ethnic groups in Nigeria. However, with the large sample size and the diverse locations, we believe our findings are generalizable to the whole population.
conclusIon
Our findings show that HLA-B*57:01 allele is very rare amongst Nigerians. While the current guidelines recommend routine screening for HLA-B*5701 prior to ABC initiation, the cost-effectiveness of this recommendation needs to be re-evaluated in Nigeria and other countries with very low prevalence of HLA-B*5701. 
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